Ken Frazier, Merck's outgoing CEO (File photo via AP)
Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med
Locked in a heated battle for I/O supremacy, Merck and Bristol have readily engaged in proxy battles for new indications, tag-teaming their blockbusters with other …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.